Scotland receives a positive recommendation by the SMC for the use of FLT3-mutation-positive targeted therapy midostaurin in first-line AML treatment.
The Scottish Medicines Consortium (SMC) have today recommended the use of midostaurin in first-line treatment for adult acute myeloid leukaemia (AML) patients, who are FMS-like tyrosine kinase 3 (FLT3) mutation-positive.
Current treatment for AML includes intensive chemotherapy, for those who are fit enough to tolerate it. It involves two phases, induction and consolidation chemotherapy. These aim to induce remission and then ensure undetectable leukaemia cells are destroyed.
Midostaurin is taken orally and is to be used in combination with current chemotherapy treatments during the induction and consolidation phases. It is then used alone (monotherapy) for 12 months, aiming to prevent the leukaemia from returning. This is known as maintenance therapy.
Read more here leukaemiacare.org.uk/suppor...
This decision follows earlier appraisal approval by NICE for England and Wales NHS use
